Apogee Therapeutics, Inc.
APGEHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Apogee Therapeutics, Inc. focuses on Biotechnology services and products. Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary. Valued at $10.07B, APGE is a large-cap name in its sector. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial.
Market Cap
$10.07B
Beta
0.33
P/E (TTM)
—
P/E (Fwd)
-25.83
EPS (TTM)
$-4.33
EPS (Fwd)
$-5.19
ROE
-28.5%
ROA
-19.0%
Cash
$1.06B
Total Debt
$8.0M
Free CF
-$142.6M
52W Change
240.9%
Annual Financials
Cash vs Debt
Apogee Therapeutics, Inc. holds $1.06B in cash against $8.0M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$142.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -28.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.33 suggests APGE is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, APGE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Apogee Therapeutics, Inc.'s trajectory.